-

Trends in High-cost Therapies: How Data Drives Market Access

-
 
 
 

Access to high-cost therapies presents a challenge to biopharma companies, payers, patients, and clinicians alike. What is the role of digital data in facilitating market access to these new products? From scoping market size and determining patient populations to partnering - with both payers and clinical sites—digital data from a variety of sources is becoming even more critical to decision-making. As these markets grow more complex, and more data becomes available from a growing number of sources including directly from patients in the form of Patient Reported Outcomes, the implications to risk management and mitigation, reinsurance, and strategies for both pharma and payers present questions across the ecosystem.

Session Host

Neil Minkoff, MD, Chief Medical Officer of Coeus Consulting Group

Dr. Minkoff serves as Chief Medical Officer of Coeus Consulting Group, a boutique life science market access firm. He founded FountainHead HealthCare in 2010 as a reaction to the ever growing complexity of the healthcare system and the need for independent thinkers who could provide some clarity in the chaos.

In 2012, Massachusetts Governor Deval Patrick appointed Dr. Minkoff as a Commissioner of the Massachusetts Group Insurance Commission, which provides oversight of health insurance for the Commonwealth of Massachusetts.

In addition to his other work, Neil B. Minkoff, MD was Chief Medical Officer from 2011-19 for a small company working on patient data where he helped develop the PRO Portal for capturing self-reported patient outcomes and clinical information to measure real-world experience, despite significant challenges. Further, Dr. Minkoff has been involved in work on 340B pricing and data and developing new drug delivery channels.

Session Participants

MacKay Jimeson, President of Ember Global Advisors

MacKay Jimeson is an award winning public affairs and communications professional, a businessman and political adviser. As President of Ember Global Advisors, Jimeson helps position companies for growth in an evolving landscape of regulation, public opinion and disruptive competition. Previously, he led Corporate Affairs for Pfizer’s $9 billion Internal Medicine business. In that role he was responsible for public policy, government affairs, communications, advocacy and corporate responsibility for a portfolio of innovative medicines that prevent strokes, manage pain and treat tobacco addiction.

Jimeson’s background in policy and public affairs were developed as an aide to Florida Governor Jeb Bush and as an advisor on Senator John McCain’s 2008 presidential campaign. Returning to his roots, Jimeson was active in Governor Bush’s 2016 presidential campaign, by serving as a policy advisor, on the national finance committee and by co-chairing Mission: NEXT, the largest Republican effort to engage millennial voters. He remains involved in politics and currently serves on the national finance committee for Texas Land Commissioner George P. Bush.

In 2016 PRWeek honored Jimeson by selecting him to their 40 under 40 list. The following year Maverick PAC, the premier national network for young conservative business professionals, named Jimeson to their list of the Future 40. In 2018 the American Council of Young Political Leaders, a program backed by the United States Department of State, selected Jimeson to serve on a seven person bipartisan delegation to Russia.


Mark Vineis, Vice President, Managed Markets, Novartis

As Vice President and Head of US Managed Markets, Mark Vineis leads a team that is re-setting the Novartis and industry standard for leadership in advancing patients’ access to medicines. In December 2020, Mark was named to the Novartis US Pharmaceutical Executive Committee, or PEC, highlighting the critical importance of his team’s work leading pricing and contracting, market access marketing, managed care, hospital systems of care, channel strategy and account management. Mark joined Novartis in June 2016 and his earlier responsibilities were commercializing the biosimilar portfolio for Sandoz Biopharmaceuticals as Vice President, Managed Markets and Specialty Services and leading pricing, contracting strategy, channel marketing and pipeline access strategy as Vice President, and leading the Access Strategy & Commercialization team.

Mark’s more than 25 years of industry experience includes leadership roles with some of the best-known global pharmaceutical companies. Prior to joining Novartis, he was the General Manager of Specialty Pharmacy for Cardinal Health. Before that, Mark spent eight years at Genentech, where he led several teams, including pricing, contracting strategy, channel strategy and managed care marketing. Earlier in his career, Mark held pricing, account management, marketing and sales roles at GlaxoSmithKline and AstraZeneca.

Mark earned a BS in Business Administration & Finance from Bloomsburg University of Pennsylvania and an MBA in Marketing from Temple University. He is certified as a pricing professional by the Professional Pricing Society.


Doug Brown, Senior Vice President of Value and Access, Coeus Consulting Group

Seasoned executive and Medicaid thought leader with deep experience working with state/national government leaders to shape Medicaid policy decisions. Extensive expertise in government healthcare programs, Medicaid, pharmaceutical pricing, Pharmacy Benefit Management, analytical skills, and public policy. A strong business development professional with a consultative style and exceptional communication skills and laser focused on the strategic initiatives necessary to achieve optimal organizational results.